Most people taking those medications, called GLP-1s, say they are spending less on eating out at restaurants and ordering takeout, according to a Morgan Stanley survey released on Tuesday.
GLP-1s include Novo Nordisk 's blockbuster weight loss injection Wegovy and diabetes counterpart Ozempic, along with Eli Lilly 's popular weight loss treatment Zepbound and diabetes injection Mounjaro.
"There is growing evidence that the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants," Morgan Stanley analysts said in the survey.
Those people are "early in their weight loss journey," but are making substantial changes to their diets and spending, according to the firm.
Roughly half of people reported cutting consumption of regular sodas, alcohol and salty snacks by 50% or more since starting on weight loss drugs.
Persons:
—, Morgan Stanley, Eli Lilly, Hollie Adams, Reuters Morgan Stanley, Morgan Stanley survery
Organizations:
Washington Post, Novo Nordisk, Reuters, Consumers
Locations:
Manhattan, London, Britain